Neuroimmunology
Autoantibodies: mechanism and testing
Dec. 20, 2024
Worddefinition
At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas.
Fingolimod …
- Updated 07.27.2021
- Released 08.12.2010
- Expires For CME 07.27.2024
Fingolimod
Introduction
Overview
Key points
Historical note and terminology
Fingolimod, first synthesized in 1992, is derived from myriocin, a metabolite of the fungus Isaria sinclairii, found to have immunosuppressive properties. Fingolimod belongs to a class of disease-modifying agents called sphingosine 1 phosphate (S1P) receptor modulators. It was originally tested in clinical trials on renal transplant patients but not found to be superior to the conventional immunosuppressant agents and, hence, not developed further for this indication. In 2010, the FDA's Peripheral and Central Nervous System Drugs Advisory Committee recommended approval of fingolimod as an oral therapy for the treatment of patients with relapsing-remitting multiple sclerosis. It is now approved for this indication in the United States, Canada, the European Union, Russia, and Australia. It is 1 of the first orally active drug therapies to be made available for the treatment of relapsing-remitting multiple sclerosis.
Pharmacology
Fingolimod is a prodrug that is phosphorylated by sphingosine kinase to active metabolite fingolimod-phosphate (S1P).
Pharmacodynamics. Fingolimod, an S1P receptor modulator, has an immunosuppressant effect in patients with multiple sclerosis. On phosphorylation, fingolimod can bind with high affinity to 4 out of 5 sub-types of S1P receptor – an extracellular lipid mediator whose major effects are mediated by G protein-coupled receptors. Persistent modulation of S1P receptor subtypes with subsequent internalization of these by fingolimod inhibits lymphocyte egress from the lymph nodes and prevents these cells from infiltrating inflammatory lesions in the CNS (01). Data from another experimental study have identified nonimmunological CNS mechanisms of fingolimod efficacy and implicate S1P signaling pathways within the CNS as targets for fingolimod therapy (06).
Fingolimod therapy affects immune cells in CSF differently from those in the blood of patients with multiple sclerosis. Fingolimod decreases the proportion of CSF CD4+ T cells but to a lesser extent than in the peripheral blood (29).
Lymphopenia produced by fingolimod differs from that caused by immunosuppressants such as azathioprine, which inhibit lymphocytes from forming, whereas fingolimod simply sequesters lymphocytes in the lymph nodes.
Prophylactic administration of fingolimod to animals with experimental autoimmune encephalitis, a model of multiple sclerosis, completely prevents development of pathological features (08). Preclinical studies suggest that fingolimod might promote neural repair in vivo (45). Fingolimod modulates multiple neuroglial cell responses, resulting in enhanced remyelination in cerebellar slice cultures with lysolecithin-induced demyelination (34).
Fingolimod attenuates ceramide-induced blood-brain barrier dysfunction in multiple sclerosis by targeting reactive astrocytes, which are the primary cellular source of enhanced ceramide production (44). Retrospective analysis of patients with relapsing-remitting multiple sclerosis with high serum levels of biomarker Sema4A who were resistant to interferon-β therapy showed that they responded with improvement on switching to fingolimod, and this correlated with lowering of Sema4A levels (27). Similar action was observed after administration of recombinant Sema4A-Fc in mice with experimental allergic encephalitis followed by fingolimod treatment. These data suggest that fingolimod can be used as a disease modifying personalized therapy for management of multiple sclerosis patients with high Sema4A levels.
Neuroprotective effect of fingolimod in vivo may result from its inhibitory action on key activation steps of astrocytes, which contribute to neuroinflammation and neurodegeneration by participating in glial scar formation as well as nitric oxide production (10). Neuroprotective effect of fingolimod on relapsing-remitting multiple sclerosis may be due to its modulatory effect on oligodendroglial cells and astrocytes as well as its direct effect on cortical neurons (36). Clinical studies including in vivo measurement of grey matter damage are required to confirm this effect.
Pharmacokinetics. After oral administration of 1 oral dose, blood concentrations of fingolimod increase steadily over the first 12 hours and remain elevated during the 24-hour period until the next dose. Pharmacokinetic profile in human patients shows a linear, dose-dependent relationship for the maximum concentration and the area under the curve. Time to maximum concentration, half-life, and clearance do not vary as the dose increases. Fingolimod has a half-life of 6 to 9 days, and steady-state pharmacokinetics are reached after 1 to 2 months of daily dosing. The phosphorylation of fingolimod to fingolimod-phosphate is reversible in plasma. As a stable equilibrium is reached between the 2, fingolimod-phosphate concentration is 2- to 4-fold higher than concentration of the parent drug. Fingolimod is also partially metabolized in the liver by cytochrome P450 to metabolites that are devoid of immunosuppressive activity and are excreted in urine and feces. Fingolimod has a predictable pharmacokinetic profile that enables effective once-daily oral dosing (11).
Local concentrations of both phosphorylated and nonphosphorylated fingolimod are much higher in lymphoid tissues than in blood, generating a reservoir in thymus and secondary lymphoid organs, which leads to sustained fingolimod production and activation of S1P within tissues. Lipophilicity of fingolimod enables crossing of the blood-brain barrier, which enhances its activity.
Pharmacogenetics/pharmacogenomics. No information is available yet.
Clinical trials
Several preliminary and phase I/II clinical trials have been conducted on fingolimod since 2006. Recommendation for approval was based on the results of 2 clinical trials.
FREEDOMS (FTY720 Research Evaluating Effects of Daily Oral therapy in Multiple Sclerosis) was a phase III, 24-month, placebo-controlled, double-blind, randomized study, conducted on patients who had relapsing-remitting multiple sclerosis and received oral fingolimod at a dose of 0.5 mg or 1.25 mg daily (24). As compared with placebo, both doses of oral fingolimod improved the relapse rate, the risk of disability progression, and end points on MRI. The investigators pointed out that these benefits will need to be weighed against possible long-term risks based on adverse events reported during the trial. A subgroup analysis of primary outcome in the FREEDOMS trial showed that patients with relapsing-remitting multiple sclerosis with a wide spectrum of clinical and MRI features can potentially benefit from treatment with 0.5 mg fingolimod (12). Findings of FREEDOMS II, a placebo-controlled, double-blind phase III study, substantiated the beneficial profile of fingolimod as a disease-modifying agent in relapsing-remitting multiple sclerosis and provided a detailed analysis of adverse effects (04). Pooling of the results of FREEDOMS I and II trials showed that over a period of 2 years the annual rates of brain volume loss was like that expected in healthy adults and was achieved in proportionately more patients with multiple sclerosis who received fingolimod than those who received placebo. Incidence of adverse events was slightly higher with fingolimod therapy than with placebo.
TRANSFORMS (Trial Assessing injectable interferon vs. FTY720 Oral in Relapsing-remitting Multiple Sclerosis) was a phase III, 12-month, double-blind, double-dummy study, in which patients with relapsing-remitting multiple sclerosis were randomly assigned to receive either oral fingolimod (0.5 mg or 1.25) daily or intramuscular interferon beta-1a weekly (09). Results showed the superior efficacy of oral fingolimod with respect to relapse rates and MRI outcomes. According to 1 comment on this study, it is still uncertain whether oral fingolimod could be used as first-line treatment or as an alternative treatment for patients who have failed immunomodulating therapy (37). Another commentary on these clinical trials suggested that only the lower dose of fingolimod (0.5 mg), which possibly has less toxicity, should be considered for prevention of relapses in relapsing-remitting multiple sclerosis (13). A randomized extension of the TRANSFORMS study showed that switching from interferon beta-1a to fingolimod led to enhanced efficacy, which was sustained with continuous use of fingolimod for 2 years (26). Within the framework of this study, measurements of the brain volume by MRI showed that fingolimod reduced brain volume loss over 12 months as compared to interferon β-1a IM in all patient subgroups, and baseline gadolinium-enhancing T1 lesion count was most predictive of change in percentage brain volume change (02).
A double-blind, randomized, parallel-group, phase II study on Japanese patients with relapsing multiple sclerosis showed clinical efficacy of fingolimod in Japanese patients that is consistent with the established effects of fingolimod in clinical trials on Caucasian patients (39).
An open-label study on patients in the real-world clinical practice setting, such as those with co-existing diseases and other medications, confirmed that the first dose of fingolimod is safe and well tolerated (31).
In INFORMS (FTY720 in Patients with Primary Progressive Multiple Sclerosis), a multicenter, double-blind, placebo-controlled parallel-group study, anti-inflammatory effects of fingolimod did not slow disease progression in patients with primary progressive multiple sclerosis (32).
A systematic review of randomized trials has shown that treatment with fingolimod compared to placebo in patients with relapsing-remitting multiple sclerosis is effective in reducing inflammatory disease activity, but it may make little or no difference in preventing worsening of disability (30). Evidence of effectiveness of fingolimod is provided by a systematic review of studies of fingolimod in the real-world practice beyond clinical trials, but some gaps remain to be investigated further due to diversity of methods used for assessing treatment benefits (47).
Indications
Fingolimod is indicated for use in relapsing-remitting multiple sclerosis.
Off-label uses
(1) Fingolimod inhibits angiogenesis and may provide a novel therapeutic approach for pathologic conditions with dysregulated angiogenesis such as cancer. | |
(2) Beyond the autoimmune indications, some studies suggest that short-term, low-dose administration of fingolimod could help treat chronic viral infections. | |
(3) Clinical severity, electrophysiological, and histological findings were ameliorated in oral fingolimod given to rats with spontaneous autoimmune polyneuropathy. | |
(4) Hemorrhagic focal encephalitis. | |
(5) Fingolimod rapidly reduces ocular infiltrates in experimental autoimmune uveoretinitis in rats and has the therapeutic potential of an acute rescue intervention for human noninfectious posterior-segment intraocular inflammatory disease. | |
(6) Administration of oral fingolimod to patients within 72 hours of intracerebral hemorrhage onset is reported to be safe, reduces cerebral edema, and attenuates neurologic deficits (15). | |
(7) An experimental study identified neuroprotective effects of fingolimod on astrocytes, ie, induction of neurotrophic mediators and inhibition of tumor necrosis factor–induced inflammatory genes, supporting the view that the effects of fingolimod may be partly mediated via astrocytes (19). | |
(8) Fingolimod improves incorporation and survival of transplanted neural stem cells in the CNS and drives their differentiation into more oligodendrocytes but fewer astrocytes, thus, promoting remyelination and CNS repair processes in situ (46). Therefore, neural stem cell-based therapy has potential application in the secondary progressive stage of multiple sclerosis. | |
(9) Fingolimod has shown neuroprotective effect in rat models of neurodegenerative disorders such as Alzheimer disease (reduction of amyloid-β production) and Huntington disease, as well as enhancement of cognitive function in multiple sclerosis patients. The neuroprotective effects exerted by fingolimod in these preclinical studies support the translation of fingolimod into clinical trials as treatment for neurodegenerative diseases beyond neuroinflammatory conditions (03). | |
(10) In animal models of epileptogenesis, fingolimod has shown antiinflammatory and neuroprotective effects, which are hypothesized to be key players in the development of epilepsy. The ameliorating effects of fingolimod shown in these studies support its further evaluation as an antiepileptogenic treatment, whether alone or in combination with other drugs. |
Contraindications
No contraindications have been defined yet.
Goals and duration of treatment
The aim is to stop the progression of multiple sclerosis and prevent relapses. The longest reported use of fingolimod in clinical trials so far is 3 years. Efficacy benefits of fingolimod during the FREEDOMS clinical trial were sustained during the extension study; annualized relapse rate and brain volume loss were reduced after switching (23). There is a case report of possible rebound of multiple sclerosis disease activity after discontinuation of fingolimod due to development of malignant melanoma (17). A real-world study in routine clinical practice has confirmed the effectiveness of fingolimod previously shown in clinical trials on multiple sclerosis patients and the practicality of quantifying clinical and MRI data collected from multiple centers using a systematic approach (48). Although fingolimod lowers the number of relapses in multiple sclerosis, it causes several side effects. This led to a study for estimating the benefit-harm balance of fingolimod using individual patient data from FREEDOMS trial, which compared 2 different dosages of fingolimod to placebo (41). Results showed that fingolimod’s net benefit did not reach the clinical relevance but the decreased risk for a decline in health over 2 years was significant and provides an objective evidence base for guideline recommendations.
Dosing
Based on clinical trials, the recommended daily oral dose of fingolimod is 0.5 mg.
Special considerations
The pharmacokinetics of fingolimod are unaffected by renal impairment or mild-to-moderate hepatic impairment. However, for patients with severe hepatic impairment, a standard first dose of fingolimod could be given followed by a maintenance dose that is reduced by half from the normal maintenance dose.
Pediatric. In a phase 3 randomized trial on pediatric patients with relapsing multiple sclerosis, fingolimod was associated with a lower rate of relapse and less accumulation of lesions on MRI over a 2-year period than interferon beta-1a, but it was associated with a higher rate of serious adverse events (05).
Geriatric. Use of fingolimod has not been tested in geriatric patients, as there were none in clinical trials. Earlier trials in renal transplant patients included older patients, but there were no specific precautions.
Pregnancy. No information is available, as pregnant and nursing women were excluded from clinical trials of fingolimod for multiple sclerosis. The number of pregnancies reported in women exposed to fingolimod in completed or ongoing clinical studies is small and does not allow firm conclusions to be drawn about fetal safety of fingolimod in humans. Because of the known risks of teratogenicity in animals, contraception is recommended in women on fingolimod therapy and for 2 months after discontinuation (25).
Anesthesia. No information is available.
Interactions
Fingolimod is not expected to interact with other drugs used for the treatment of multiple sclerosis, as most of these do not metabolize via P450 4F2/3 enzyme pathway. However, ketoconazole increases fingolimod blood levels in a drug interaction via CYP4F2 inhibition (28).
Immune checkpoint inhibitors such as pembrolizumab are effective anticancer agents and antitumor immune responses are associated with a stronger presence of tumor-infiltrating lymphocytes in solid tumor tissue (21). In cancer patients with relapsing-remitting multiple sclerosis who are under continuous treatment with fingolimod, which inhibits lymphocyte egress from secondary lymphatic organs, the efficacy of immune checkpoint inhibitors may be reduced. In patients with relapsing-remitting multiple sclerosis who developed various cancers during fingolimod treatment, histology of all tumors consistently showed low numbers of tumor-infiltrating lymphocytes but a second biopsy taken from 1 of the tumors showed a significant increase of tumor-infiltrating lymphocytes after stopping fingolimod and starting pembrolizumab, indicating a surge in the number tumor-infiltrating lymphocytes (16).
Adverse effects
Adverse events during clinical trials include bradycardia and atrioventricular block, respiratory and herpesvirus infections, increased liver enzyme levels, hypertension, and macular edema (20). Paroxysmal atrial fibrillation has been reported after initiating fingolimod therapy (38).
Cerebral vasospasm has been reported during fingolimod treatment in a patient with multiple sclerosis (40). Animal experimental studies show that S1P induces vasoconstriction in coronary arteries by directly activating S1P-3 receptor and through a subsequent increase in calcium ions and Rho activation in vascular smooth muscle cells. Vasoconstriction can be counteracted by TY-52156, which is an S1P-3 receptor-specific antagonist (35).
Macular edema was reported in 0.5% of patients treated with fingolimod in the FREEDOMS and TRANSFORMS trials (22). Macular edema appears to be dose-dependent as it occurred in only 2 patients taking the lower 0.5 mg dose and resolved following discontinuation of therapy. Macular edema has been reported to be successfully managed in a case by topical antiinflammatory drugs (07). Retinal hemorrhages and retinal vein occlusion have also been reported, which may not resolve with discontinuation of fingolimod alone but may require intravitreal therapy (33).
Of the 19 cases of fingolimod-associated progressive multifocal leukoencephalopathy reported worldwide by the end of 2017, 4 cases were from Japan, and there is a suspicion of dose sensitivity in Japanese multiple sclerosis patients, as recovery of lymphocyte counts in the peripheral blood after reduction of dosage of fingolimod is worse in patients who receive long-term fingolimod treatment than in patients who receive short-term fingolimod treatment (42).
Fingolimod therapy markedly reduces lymphocyte counts in peripheral blood of multiple sclerosis patients, and subgroup analysis of T cells showed that naïve and central memory T helper cells are the most severely affected (18). Long-term treatment with fingolimod is associated with a small increase in the risk of herpes virus reactivation and respiratory tract infections. A patient with a relapsing remitting multiple sclerosis under fingolimod treatment developed a severe COVID-19 infection with bilateral interstitial pneumonia but improved following discontinuation of fingolimod and intensive care (14).
Macular edema has been reported in a multiple sclerosis patient who presented with an acute decrease in vision in the left eye during treatment with fingolimod, and the diagnosis was confirmed on fluorescein angiogram and optical coherence tomography (43). Macular edema resolved completely after discontinuation of fingolimod and treatment with a topical corticosteroid.
A patient in Europe with a diagnosis of possible multiple sclerosis has been reported to have developed progressive multifocal leukoencephalopathy following fingolimod therapy. According to an alert issued by the FDA in 2013, physicians in the United States are requested to report any similar adverse event.
References
- 01
- Aktas O, Küry P, Kieseier B, Hartung HP. Fingolimod is a potential novel therapy for multiple sclerosis. Nat Rev Neurol 2010;6(7):373-82. PMID 20551946
- 02
- Barkhof F, de Jong R, Sfikas N, et al. The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis. Mult Scler 2014;20(13):1704-13. PMID 24812043
- 03
- Bascuñana P, Möhle L, Brackhan M, Pahnke J. Fingolimod as a treatment in neurologic disorders beyond multiple sclerosis. Drugs R D 2020;20(3):197-207.** PMID 32696271
- 04
- Calabresi PA, Radue EW, Goodin D, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 2014;13(6):545-56. PMID 24685276
- 05
- Chitnis T, Arnold DL, Banwell B, et al. Trial of fingolimod versus interferon beta-1a in pediatric multiple sclerosis. N Engl J Med 2018;379(11):1017-27.** PMID 30207920
- 06
- Choi JW, Gardell SE, Herr DR, et al. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc Natl Acad Sci U S A 2011;108(2):751-6. PMID 21177428
- 07
- Chui J, Herkes GK, Chang A. Management of fingolimod-associated macular edema. JAMA Ophthalmol 2013;131(5):694-6. PMID 23538612
- 08
- Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol 2010;33(2):91-101. PMID 20061941
- 09
- Cohen JA, Barkhof F, Comi G, et al; TRANSFORMS Study Group. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362(5):402-15. PMID 20089954
- 10
- Colombo E, Di Dario M, Capitolo E, et al. Fingolimod may support neuroprotection via blockade of astrocyte nitric oxide. Ann Neurol 2014;76(3):325-37.** PMID 25043204
- 11
- David OJ, Kovarik JM, Schmouder RL. Clinical pharmacokinetics of fingolimod. Clin Pharmacokinet 2012;51(1):15-28. PMID 22149256
- 12
- Devonshire V, Havrdova E, Radue EW, et al. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. Lancet Neurol 2012;11(5):420-8. PMID 22494956
- 13
- Doggrell SA. Oral fingolimod for relapsing-remitting multiple sclerosis. Expert Opin Pharmacother 2010;11(10):1777-81. PMID 20408749
- 14
- Foerch C, Friedauer L, Bauer B, Wolf T, Adam EH. Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod. Mult Scler Relat Disord 2020;42:102180.** PMID 32408155
- 15
- Fu Y, Hao J, Zhang N, et al. Fingolimod for the treatment of intracerebral hemorrhage: a 2-arm proof-of-concept study. JAMA Neurol 2014;71(9):1092-101. PMID 25003359
- 16
- Hasan Ali O, Berner F, Ackermann CJ, et al. Fingolimod and tumor-infiltrating lymphocytes in checkpoint-inhibitor treated cancer patients. Cancer Immunol Immunother 2021;70(2):563-8.** PMID 32804246
- 17
- Havla JB, Pellkofer HL, Meinl I, Gerdes LA, Hohlfeld R, Kümpfel T. Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment. Arch Neurol 2012;69(2):262-4. PMID 22332194
- 18
- Hjorth M, Dandu N, Mellergård J. Treatment effects of fingolimod in multiple sclerosis: Selective changes in peripheral blood lymphocyte subsets. PLoS One 2020;15(2):e0228380. PMID 32012202
- 19
- Hoffmann FS, Hofereiter J, Rübsamen H, et al. Fingolimod induces neuroprotective factors in human astrocytes. J Neuroinflammation 2015;12:184. PMID 26419927
- 20
- Horga A, Castilló J, Montalban X. Fingolimod for relapsing multiple sclerosis: an update. Expert Opin Pharmacother 2010;11(7):1183-96. PMID 20367536
- 21
- Jain KK. Personalized immuno-oncology. Med Princ Pract 2021;30(1):1-16. PMID 32841942
- 22
- Jain N, Bhatti MT. Fingolimod-associated macular edema: incidence, detection, and management. Neurology 2012;78(9):672-80. PMID 22371414
- 23
- Kappos L, O'Connor P, Radue EW, et al. Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial. Neurology 2015;84(15):1582-91. PMID 25795646
- 24
- Kappos L, Radue EW, O'Connor P, et al; FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362(5):387-401. PMID 20089952
- 25
- Karlsson G, Francis G, Koren G, et al. Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis. Neurology 2014;82(8):674-80. PMID 24463630
- 26
- Khatri B, Barkhof F, Comi G, et al; TRANSFORMS Study Group. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol 2011;10(6):520-9. PMID 21571593
- 27
- Koda T, Namba A, Nakatsuji Y, et al. Beneficial effects of fingolimod in MS patients with high serum Sema4A levels. PLoS One 2018;13(3):e0193986.** PMID 29518148
- 28
- Kovarik JM, Dole K, Riviere GJ, et al. Ketoconazole increases fingolimod blood levels in a drug interaction via CYP4F2 inhibition. J Clin Pharmacol 2009;49(2):212-8. PMID 19118083
- 29
- Kowarik MC, Pellkofer HL, Cepok S, et al. Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS. Neurology 2011;76(14):1214-21. PMID 21464424
- 30
- La Mantia L, Tramacere I, Firwana B, Pacchetti I, Palumbo R, Filippini G. Fingolimod for relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev 2016;4:CD009371.** PMID 27091121
- 31
- Laroni A, Brogi D, Morra VB, et al. Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial. BMC Neurol 2014;14(1):65. PMID 24690227
- 32
- Lublin F, Miller DH, Freedman MS, et al. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2016;387(10023):1075-84.** PMID 26827074
- 33
- Mandal P, Gupta A, Fusi-Rubiano W, Keane PA, Yang Y. Fingolimod: therapeutic mechanisms and ocular adverse effects. Eye (Lond) 2017;31(2):232-40. PMID 27886183
- 34
- Miron VE, Ludwin SK, Darlington PJ, et al. Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices. Am J Pathol 2010;176(6):2682-94. PMID 20413685
- 35
- Murakami A, Takasugi H, Ohnuma S, et al. Sphingosine 1-phosphate (S1P) regulates vascular contraction via S1P3 receptor: investigation based on a new S1P3 receptor antagonist. Mol Pharmacol 2010;77(4):704-13. PMID 20097776
- 36
- Pitteri M, Magliozzi R, Bajrami A, Camera V, Calabrese M. Potential neuroprotective effect of Fingolimod in multiple sclerosis and its association with clinical variables. Expert Opin Pharmacother 2018;19(4):387-95. PMID 29397790
- 37
- Pozzilli C, Prosperini L, Borriello G. Treating multiple sclerosis with fingolimod or intramuscular interferon. Expert Opin Pharmacother 2010;11(11):1957-60. PMID 20426705
- 38
- Rolf L, Muris AH, Damoiseaux J, van Daele M, Hupperts R. Paroxysmal atrial fibrillation after initiation of fingolimod for multiple sclerosis treatment. Neurology 2014;82(11):1008-9. PMID 24523479
- 39
- Saida T, Kikuchi S, Itoyama Y, et al. A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis. Mult Scler 2012;18(9):1269-77. PMID 22354739
- 40
- Schwarz A, Korporal M, Hosch W, Max R, Wildemann B. Critical vasospasm during fingolimod (FTY720) treatment in a patient with multiple sclerosis. Neurology 2010;74(24):2022-4. PMID 20548047
- 41
- Spanu A, Aschmann HE, Kesselring J, Puhan MA. Benefit-harm balance of fingolimod in patients with MS: a modelling study based on FREEDOMS. Mult Scler Relat Disord 2020;46:102464. PMID 32889373
- 42
- Takahashi K. Effect of dosage reduction on peripheral blood lymphocyte count in patients with multiple sclerosis receiving long-term fingolimod therapy.** J Clin Neurosci 2019;63:91-4. PMID 30772201
- 43
- Turaka K, Bryan JS. Does fingolimod in multiple sclerosis patients cause macular edema. J Neurol 2012;259(2):386-8. PMID 22231867
- 44
- van Doorn R, Nijland PG, Dekker N, et al. Fingolimod attenuates ceramide-induced blood-brain barrier dysfunction in multiple sclerosis by targeting reactive astrocytes. Acta Neuropathol 2012;124(3):397-410. PMID 22810490
- 45
- Vasiliou S. Oral fingolimod for the treatment of relapsing-remitting multiple sclerosis. Drugs Today (Barc) 2010;46(5):315-25. PMID 20517533
- 46
- Zhang Y, Li X, Ciric B, et al. Effect of fingolimod on neural stem cells: a novel mechanism and broadened application for neural repair. Mol Ther 2017;25(2):401-5. PMID 28153091
- 47
- Ziemssen T, Medin J, Couto CA, Mitchell CR. Multiple sclerosis in the real world: a systematic review of fingolimod as a case study. Autoimmun Rev 2017;16(4):355-76.** PMID 28212923
- 48
- Zivadinov R, Medin J, Khan N, et al. Impact of fingolimod on clinical and magnetic resonance imaging outcomes in routine clinical practice: a retrospective analysis of the multiple sclerosis, clinical and MRI outcomes in the USA (MS-MRIUS) study. Mult Scler Relat Disord 2019;27:65-73.** PMID 30342416
Contributors
All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.
Author
-
K K Jain MD†
Dr. Jain was a consultant in neurology and had no relevant financial relationships to disclose.
See Profile
This is an article preview.
Start a Free Account
to access the full version.
-
Nearly 3,000 illustrations, including video clips of neurologic disorders.
-
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
-
Full spectrum of neurology in 1,200 comprehensive articles.
-
Listen to MedLink on the go with Audio versions of each article.
Questions or Comment?
MedLink®, LLC
3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Also in This Category
-
-
Neuroimmunology
Multiple sclerosis: treatment of its symptoms
Oct. 30, 2024
-
Neuroimmunology
Anti-GQ1b antibody syndrome
Oct. 23, 2024
-
Neuropharmacology & Neurotherapeutics
Serotonin syndrome
Oct. 21, 2024
-
Neuro-Oncology
Paraneoplastic syndromes
Oct. 15, 2024
-
Neuroimmunology
Anti-IgLON5 disease
Oct. 10, 2024
-
Neuroimmunology
Balo concentric sclerosis
Oct. 04, 2024
-
Neuro-Oncology
Anti-LGI1 encephalitis
Oct. 03, 2024